NCI

Receptor’s role in stopping H. pylori

The immune receptor NOD1 may be a prime target for preventing or treating H. pylori infections — the most significant risk factor for stomach cancer, Vanderbilt researchers have discovered.

Low oxygen and antibody responses

Mark Boothby and colleagues are exploring the factors that contribute to antibody production and quality, which are key to our defense against pathogens and response to vaccines.

Pathways of radiosensitization

Austin Kirschner and colleagues demonstrate how a hormone therapy for prostate cancer improves radiation’s tumor-killing power.

Cancer’s SOS

Stephen Fesik and colleagues are advancing cancer drug discovery with the characterization of small molecules that modulate RAS, an important target for anti-cancer therapies.

Unraveling endocytosis

New discoveries by Jason MacGurn and colleagues further understanding of the complex machinery that cells use take up substances from outside the cell.

Cancer prevention drug also disables H. pylori bacterium

A medicine currently being tested as a chemoprevention agent for multiple types of cancer has more than one trick in its bag when it comes to preventing stomach cancer, Vanderbilt researchers have discovered.

1 7 8 9 10 11 28